Tyrosine kinase inhibitors (TKIs) that act on the MAPK/ERK pathway, such as regorafenib, have also demonstrated clinical activity; regorafenib not only induces apoptosis but suppresses MAPK/NF-κB–mediated tumor progression in BC [87, 88]. Here, MAPK1 is linked to neoplasm.